The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
Related Posts
Tesla investors are growing wary of Elon Musk’s futuristic promises
Tesla shares plummeted as CEO Elon Musk’s promises for robotaxis failed to excite investors following another disappointing earnings report.
Implemented or not, Trump’s 25% tariff threat is challenging the auto industry
On a sales basis, German automaker Volkswagen is the most exposed to tariff risk, followed by Nissan Motor and Stellantis, S&P Mobility reports.
Goldman Sachs CEO Solomon says IPO market is ‘going to pick up’ along with dealmaking
At an event hosted by Cisco on Wednesday, Goldman Sachs CEO David Solomon indicated that the multi-year IPO drought should be coming to an end.